Casi pharmaceuticals announces its partner, precision autoimmune therapeutics co., ltd has completed first-round financing of $21 million

~ precision autoimmune therapeutics (pat) announced the completion of first-round financing of the equivalent of approximately us $21 million ~ ~ casi holds 15% equity stake in pat ~ ~ pat will pay casi us $5 million equivalent as the first installment of upfront payment of the cid-103 sub-license agreement ~ rockville, md. and beijing , july 8, 2022 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that precision autoimmune therapeutics co., ltd.
CASI Ratings Summary
CASI Quant Ranking